Table 1.
Baseline biochemical and physical characteristics of the study populations.
| HCV genotype 1 (n = 15) |
Control genotype 1 (n = 5) |
HCV genotype 3 (n = 22) |
Control genotype 3 (n = 5) |
|
|---|---|---|---|---|
| Gender (male/female) | 8/7 | 2/3 | 10/12 | 2/3 |
| Age (years) | 48.1 ± 12.6 | 49.3 ± 10.3 | 37.5 ± 9.5 | 49.3 ± 10.3 |
| ALT U/l) | 80.2 ± 69.3 | 61.4 ± 40.9 | 40.5 ± 34.2 | 61.4 ± 40.9 |
| AST (U/l) | 76.7 ± 67.6 | 37.4 ± 17.6 | 58.4 ± 32.1 | 37.4 ± 17.6 |
| γ-GT (U/l) | 133.7 ± 23.3 | 60 ± 29.8 | 97.8 ± 10.6 | 60 ± 29.8 |
| Total bilirubin (mg/dl) | 1.4 ± 0.2 | 0.7 ± 0.2 | 0.9 ± 0.5 | 0.7 ± 0.2 |
| Prothrombin time (%) | 103 ± 11.2 | 108.6 ± 12.1 | 114 ± 9 | 108.6 ± 12.1 |
| Triglycerides (mg/dl) | 153.2 ± 94.3 | 137.6 ± 62.9 | 194.5 ± 86.2 | 137.6 ± 62.9 |
| Cholesterol (mg/dl) | 201.8 ± 52.5 | 201 ± 43.6 | 208.6 ± 37.2 | 201 ± 43.6 |
| Virological response | 11/4 (73.3%) | / | 19/3 (86.3%) | / |
| Ascites | None | none | none | none |
| FibroScan (kPa) Pre-therapy |
8.8 ± 5.4 | 9.8 ± 3.9 | 7.5 ± 1.9 | 8.2 ± 2.4 |
| FibroScan (kPa) Post-therapy |
7.4 ± 1.8 | 9.5 ± 3.3 | 6.2 ± 1.2 | 8.7 ± 2.9 |
Values are presented as means ± SD. Genotype 1 was present in 15 patients with hepatitis C whereas 22 patients had genotype 3. Additionally, a group of 10 subjects with untreated HCV was used as a control. No relationship was found between BIA measurements and laboratory data.